Liposomes, part D edited by Nejat Düzgüneş

Section I. Antibody-or ligand-targeted liposomes --1. High-yield coupling of antibody fab fragments to liposomes containing maleimide-functionalized lipids --2. Interactions of hyaluronan-targeted liposomes with cultured cells: modeling of binding and endocytosis --3. Folate receptor-mediated targeting of liposomal drugs to cancer cells --4. Preparation of poly(ethylene glycol)-grafted liposomes with ligands at the extremeties of polymer chains --Section II. Environment-sensitive liposomes --5. Temperature-sensitive liposomes --6. The materials engineering of temperature-sensitive liposomes --7. Tunable pH-sensitive liposomes --8. Sterically stabilized pH-sensitive liposomes --9. Improved preparation of PEG-diortho ester-diacyl glycerol conjugates --10. Preparation of plasmenylcholine lipids and plasmenyl-type liposome dispersions --Section III. Liposomal oligonucleotides --11. High efficiency entrapment of antisense oligonucleotides in liposomes --12. Cationic liposomes/ lipids for oligonucleotide delivery: application to the inhibition of tumorigenicity of Kaposi's Sarcoma by vascular endothelial growth factor antisense oligodeoxynucleotides --13. Requirements for delivery of active antisense oligonucleotides into cells with lipid carriers --14. Mass spectrometry and enzyme-linked immunosorbent assay methods for the quantitation of liposomal antisense oligonucleotide (LE-rafAON) in human plasma --15. Liposomal antisense oligonucleotides for cancer therapy --Section IV. Liposomes in vivo --16. Biodistribution and uptake of liposomes in vivo --17. Transport of liposome-entrapped substances into skin as measured by electron paramagnetic resonance oximetry in vivo --18. Liposomal gels for vaginal drug delivery --19. Use of nitroxides to protect liposomes against oxidative damage